FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileIsland Pharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
ILA.AX
Island Pharmaceuticals Limited Stock AnalysisComprehensive stock analysis for Island Pharmaceuticals Limited (ILA.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisILA.AX
ILA.AX
Island Pharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
ILA.AX
  1. Home
  2. Stocks
  3. Island Pharmaceuticals Limited

Island Pharmaceuticals Limited

🇦🇺ILA.AX•ASX

Island Pharmaceuticals Limited

🇦🇺ILA.AX•ASX

Your view on ILA.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Island Pharmaceuticals Limited

Industry
Biotechnology
Sector
Healthcare
CEO
David Charles Foster
Headquarters
117 Camberwell Road, Hawthorn East, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
David Charles Foster
Headquarters
117 Camberwell Road, Hawthorn East, VIC, AU
Description

Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections.

Its lead therapeutic agent, ISLA-101, is currently under development for both preventing and treating dengue fever and other illnesses transmitted by mosquitoes.

The company participates in various strategic collaborations, including a research partnership with Monash University to evaluate known molecules against host targets, and a research and development alliance with Griffith University aimed at screening for active antiviral compounds through a systematic repurposing approach.

Additionally, Island Pharmaceuticals has a research agreement with Compounds Australia, providing access to an extensive drug library containing roughly 4,500 molecules for potential drug repurposing and pipeline enhancement.

In anticipation of its ISLA-101 Phase II clinical study, the company has also established a cooperative research and development pact with the U.S. Army.

Other key agreements include a supply contract with Catalent for the production of Fenretinide softgels for individuals participating in dengue fever trials, and the entitlement to reference the National Cancer Institute's Investigational New Drug (IND) application for ISLA-101. The company, founded in 2017, is based in Camberwell, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Island Pharmaceuticals Limited. Starting points for Island Pharmaceuticals Limited: EPS -AUD 0.03, beta 0.12 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Island Pharmaceuticals Limited. Island Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Island Pharmaceuticals Limited. Trailing twelve-month EPS for Island Pharmaceuticals Limited stands at -AUD 0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis quarterSep 2025Next quarterJun 2026This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 0.00−AUD 0.01−AUD 0.05AUD 1.28
Lowest estimateAUD 0.00−AUD 0.01−AUD 0.05AUD 1.28
Highest estimateAUD 0.00−AUD 0.01−AUD 0.05AUD 1.28
Number of analysts0111
A year ago——−AUD 0.041—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterSep 2025Next quarterJun 2026This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 22197.00AUD 0.00AUD 480.80MAUD 642.90M
Lowest estimateAUD 22197.00AUD 0.00AUD 480.80MAUD 642.90M
Highest estimateAUD 22197.00AUD 0.00AUD 480.80MAUD 642.90M
Number of analysts1011
A year ago——AUD 0.00—
Growth vs a year ago————

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Island Pharmaceuticals Limited. Island Pharmaceuticals Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ILA.AX14 companies
Compare ILA.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
BIT.AXBiotron LimitedHealthcareBiotechnology—
RCE.AXRecce Pharmaceuticals LtdHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
OCC.AXOrthocell LimitedHealthcareASX—
OCEAOcean Biomedical, Inc.HealthcarePNK$1.2M
OCGNOcugen, Inc.HealthcareNASDAQ$250.8M
OCSOculis Holding AGHealthcareNASDAQ$456.2M
OCULOcular Therapeutix, Inc.HealthcareNASDAQ$1.3B
ODTXOdyssey Therapeutics, Inc.HealthcareNASDAQ$912.3M
OGENOragenics, Inc.HealthcareAMEX$852,760
OKUROnKure Therapeutics, Inc.HealthcareNASDAQ$114.2M
OKYOOKYO Pharma LimitedHealthcareNASDAQ$57.7M
OLMAOlema Pharmaceuticals, Inc.HealthcareNASDAQ$618.5M
OMEROmeros CorporationHealthcareNASDAQ$1.1B
ONCBeOne Medicines Ltd.HealthcareNASDAQ$43.1B
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Island Pharmaceuticals Limited.

ILA.AX AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1